Harrow Health, Inc. 11.875% Senior Notes due 2027
HROWM
Updated: 22/09/2026, 18:11:20
Harrow Health, Inc. focuses on the creation, production, and marketing of cutting-edge pharmaceutical solutions. Its business activities are primarily organized into two distinct divisions: Pharmaceutical Compounding and Pharmaceutical Drug Development. Specifically, the Pharmaceutical Compounding segment oversees the operations of the ImprimisRx enterprise. The company was established in January 2006 by Mark L. Baum and Robert J. Kammer, and its main corporate office is located in Nashville, Tennessee.
No summaries found.
- Share price
- $26.03
- Market cap
- $1.34B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Mark L. Baum
- Employees
- 217
- IPO date
- 29/12/2022
- Beta
- 0.13720348
- Last dividend
- $0.00
- Day range
- $26.03 – $26.07
- 52-week range
- $24.90 – $27.70
- 1-day performance
- -0.08%
- 1-year performance
- 4.53%
- Current drawdown (1Y)
- -6.03%
- CIK
- 0001360214
- CUSIP
- N/A
- ISIN
- US4158583074
- Created
- 07/12/2025, 04:35:27
- Last update
- 22/09/2026, 18:11:20
Track Harrow Health, Inc. 11.875% Senior Notes due 2027 with an AI analyst
See which prediction-market events move HROWM, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
No news found for this symbol.